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Cardiovascular events remain one of the most frequent causes of mortality and morbidity worldwide. The majority of cardiac events occur in
individuals without known coronary artery disease (CAD) and in low- to intermediate-risk subjects. Thus, the development of improved
preventive strategies may substantially benefit from the identification, among apparently intermediate-risk subjects, of those who have a
high probability for developing future cardiac events. Cardiac computed tomography and myocardial perfusion scintigraphy (MPS) by
single photon emission computed tomography may play a role in this setting. In fact, absence of coronary calcium in cardiac computed tom-
ography and inducible ischaemia in MPS are associated with a very low rate of major cardiac events in the next 3–5 years. Based on current
evidence, the evaluation of coronary calcium in primary prevention subjects should be considered in patients classified as intermediate-risk
based on traditional risk factors, since high calcium scores identify subjects at high-risk who may benefit from aggressive secondary preven-
tion strategies. In addition, calcium scoring should be considered for asymptomatic type 2 diabetic patients without known CAD to select
those in whom further functional testing by MPS or other stress imaging techniques may be considered to identify patients with significant
inducible ischaemia. From available data, the use of MPS as first line testing modality for risk stratification is not recommended in any category
of primary prevention subjects with the possible exception of first-degree relatives of patients with premature CAD in whom MPS may be
considered. However, the Working Group recognizes that neither the use of computed tomography for calcium imaging nor of MPS have
been proven to significantly improve clinical outcomes of primary prevention subjects in prospective controlled studies. This information
would be crucial to adequately define the role of imaging approaches in cardiovascular preventive strategies.
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Preamble
Despite dramatic decrease in mortality over the past decades, car-
diovascular diseases remain the most frequent cause of death
worldwide.1,2 To decrease the burden of cardiovascular mortality
and morbidity, primary and secondary prevention strategies have
been advocated by current prevention guidelines.3 It is known
that primary prevention interventions are more effective in
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terms of absolute number of prevented deaths compared with
interventions in secondary prevention populations.4 Although
this may appear paradoxical considering the higher cardiovascular
risk of patients experiencing prior cardiovascular events, it is easily
explained by the fact that people without a previous event
(primary prevention) represent the vast majority of the population.
Therefore, the concept of risk stratification of asymptomatic indi-
viduals without previous cardiovascular events has been
implemented in prevention guidelines to identify subjects at high
cardiovascular risk in whom secondary prevention strategies,
including drug therapy, are recommended. Yet, only a minority
of asymptomatic individuals are classified as high risk and, conse-
quently, the majority of events occurs in subjects at low to inter-
mediate risk, a phenomenon known as the Rose’ paradox.5 As
recently pointed out by Bonow,6 this phenomenon holds true
for all screening modalities. To overcome this limitation, several
new biomarkers and imaging variables have been proposed to
refine current risk calculation based on traditional risk factors
and to reclassify asymptomatic subjects, reducing the proportion
currently classified at intermediate risk in whom appropriate man-
agement of risk factors is often unclear.3,7 In addition, although
type 2 diabetic patients are considered at high risk by current
guidelines and secondary prevention measures are recommended,
some patients may in fact have silent ischaemia and severe coron-
ary artery disease (CAD) which may benefit from even more
aggressive measures, including coronary revascularization.
For the identification of asymptomatic individuals with high car-
diovascular event risk who would benefit from more aggressive
prevention measures, and of diabetic patients with severe CAD
who might benefit from revascularization, imaging approaches
may be useful. Direct visualization of the coronary arteries by com-
puted tomography (CT) and imaging of perfusion by myocardial
perfusion scintigraphy (MPS) have been investigated in this
context. The purpose of this position paper is to summarize
current evidence on the value of cardiac CT and MPS for risk stra-
tification and the impact on clinical outcome of asymptomatic sub-
jects. Special consideration is given to individuals with type 2
diabetes and other patient groups with a higher baseline risk, for
example due to familial hypercholesterolaemia or in relatives of
patients with premature CAD. The document represents the
opinion of the Working Group on Nuclear Cardiology and
Cardiac CT of the European Society of Cardiology and intends
to foster future research in this field.
The anatomical and
pathophysiological basis for risk
evaluation with cardiac computed
tomography and myocardial
perfusion scintigraphy
Prevention of cardiac events in asymptomatic subjects without
known CAD may follow two complementary strategies: (i) pre-
vention of development, progression, and complications of
atherosclerosis (reduction of CAD substrate), and, in a minority
of subjects, (ii) identification and treatment (including
revascularization) of patients with a prognostically relevant
ischaemic burden.
Most available studies that evaluate the prognostic power of
diagnostic tests are focused on the prediction of hard cardiac
events, usually acute myocardial infarction (MI) and cardiac
death. Obviously, this approach intrinsically implies that these
events are precipitated by the same mechanism(s) and, hence,
that an abnormality would predict the future risk for both of
these events in the same way. Yet, this assumption has not been
conclusively proven. While it is true that sudden death can rep-
resent an early complication of an acute MI, it can also occur in
the absence of myocardial necrosis,8 for example in the context
of a transient ischaemic episode. On the other hand, although
severe coronary stenoses are more prone to instability, acute MI
often occurs at the site of non-haemodynamically significant
plaques (which represent the majority of atherosclerotic
lesions9) and in non-previously ischaemic myocardial regions.10,11
In fact, it has been reported that following ischaemia detection,
acute cardiac events are more likely to occur at the site of the hae-
modynamically significant stenosis, whereas events occurring at
distance (more than 2 years) from ischaemia detection more
likely develop from instabilization of coronary stenosis remote to
the site of ischaemia.12
These considerations suggest that the two major complications
of CAD might only partially share common underlying mechanisms
and this needs to be taken into account when cardiac CT and MPS
are considered for risk stratification. In fact, coronary morphology
and atherosclerotic burden, as assessed with cardiac CT, do not
accurately predict the functional/pathophysiological effects of epi-
cardial stenosis on myocardial perfusion, which is also subject to
influence by impaired endothelial function and loss of integrity of
microcirculation.13 Accordingly, a functional approach using MPS
would be more useful to identify candidates for revascularization
based on the quantification of ischaemia, especially in the presence
of intermediate coronary stenosis and to predict cardiac events in
the short term14 (1–2 years), whereas the evaluation of the ather-
osclerotic burden by cardiac CT would be more useful for inter-
vention strategies aimed at reducing the progression of
atherosclerosis and lowering the long-term rate of CAD events
in less selected populations.
Coronary artery calcium
In the coronary arteries, calcifications occur almost exclusively in
the context of atherosclerosis.15 The only exception are patients
in renal failure, in whom medial (non-atherosclerotic) calcification
of the coronary artery wall may occur in addition to atherosclero-
tic calcification. In fact, coronary calcium is considered to provide
an estimate of the vascular biological age.16 It has been shown that
the amount of Coronary Artery Calcium (CAC) reflects the total
atherosclerotic burden, including both calcified and non-calcified
plaques.17 The quantitative relationship between calcified and non-
calcified plaque components is not uniform, and, in some individ-
uals, purely non-calcified plaques may be present, which in part
explains the occasional occurrence of cardiac events in subjects
with no detectable coronary calcification. Coronary Artery
Calcium can be detected in non-contrast cardiac CT data sets. In
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order to quantify CAC, the area and density of calcified deposits
are measured. Several quantification methods, including the ‘Agat-
ston Score’ as well as the calcified volume or the derived calcium
mass,18 and recently a calcium coverage score, defined as the per-
centage of coronary arteries affected by calcified plaque,19 have
been proposed for clinical use. To date, the ‘Agatston Score’
remains the most commonly used measure because most previous
large-scale trials and cross-sectional studies used this method, so
that large reference data sets exist. ‘Agatston Scores’ are often
classified as to their severity and meaning as listed in Table 1.20
However, these categories are purely empirical. The prevalence
and extent of CAC increases with age and is more severe in
men compared with women.21 A direct comparison of the prog-
nostic value between absolute CAC scores and calcium ‘percen-
tiles’ relative to age and gender has been recently reported by
the Multi-Ethnic Study of Atherosclerosis (MESA) investigators.22
In this study, although both methods yielded effective risk stratifi-
cation, the absolute measurement approach performed better than
the percentile approach. Therefore, reporting the absolute CAC
score is currently recommended for clinical practice.
Prognostic value of coronary artery
calcium in asymptomatic subjects
In asymptomatic individuals, the absence of detectable CAC is
associated with a very low (,1% per year) risk of major cardiovas-
cular events over the next 3–5 years, whereas an up to 11-fold
increase of the risk for major cardiac events has been reported
in asymptomatic subjects with extensive coronary calcification
(‘Agatston Score’ .1000).20,23,24 Not all published studies
provide a realistic estimate of the relative risk for future cardiovas-
cular events in asymptomatic individuals with detectable coronary
calcification. This is due to limitations of some published studies,
including self-referral of participants instead of general populations,
unblinded outcomes adjudication, and self-reported instead of
measured risk factors.20 However, results of several large
population-based studies have now become available and provide
evidence for the incremental prognostic value of CAC as quanti-
fied by CT. In asymptomatic subjects without known CAD, CAC
is predictive of future hard cardiovascular events above and
beyond traditional risk factors, as determined by the significant
increase in the area under the receiver operator characteristics
curves.22,25,26 The recent population-based MESA study, con-
ducted in 6722 asymptomatic subjects belonging to four racial
groups and followed for 3.8 years, demonstrated a significant
difference in the prevalence of CAC among different ethnic
groups (from 70% in white men to 52% for black men) but
similar incremental prognostic value of CAC scores over tra-
ditional risk factors, with a seven-fold increase in the incidence
of CAD events for ‘Agatston Scores’ .100 when compared
with individuals without CAC.23
For clinical decision making, the additional risk of cardiac events
associated with CAC in each conventional risk categories may be
important to appropriately reclassify subjects. In a prospective
population analysis of 1461 individuals, it was observed that
cardiac event rates increased with increasing CAC scores in each
Framingham risk category, including low-risk, intermediate-risk,
and high-risk individuals.26 However, in individuals classified as
low risk by the Framingham method, high CAC scores (‘Agatston
Score’ .300) are infrequently found and the affected group of
individuals despite increased risk remains, as a population, below
the current risk threshold set by guidelines for implementation
of aggressive risk factors modification26 (Figure 1). This suggests
that CAC imaging as screening modality would not be currently
useful or cost-effective in this population although still relevant
in selected individual subjects. Similarly, in the high-risk group
(based on Framingham or other risk scores), a low CAC score
does not reclassify subjects to low risk and would therefore not
justify to avoid therapy for risk reduction, as currently rec-
ommended by guidelines.3,7
However, CAC assessment may be beneficially used in inter-
mediate risk patients in whom the required intensity of risk
factor modification is often uncertain.3,7 In this category, a high
CAC score clearly identifies a group of high-risk subjects, in
whom intensive treatment of risk factors may be warranted,
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Table 1 Classification of coronary calcium score
Absolute value (Agatston units) Ranking
0 Absent
.0,10 Minimal
≥10,100 Mild
≥100,400 Moderate
≥400,1000 Severe
≥1000 Extensive
Classification of coronary calcium absolute content evaluated by cardiac CT and
quantified by Agatston units.
Figure 1 Predicted event rates for Coronary Artery Calcium
Score in relation to Framingham risk categories. Predicted
7-year event rates from COX regression model for coronary
artery disease death or non-fatal MI for categories of Framingham
risk score (FRS) or coronary artery calcium score (CACS) in sub-
jects without previous cardiovascular disease reported by Green-
land et al. In intermediate FRS risk patients, a CACS .300
Agatston units identifies subjects at high cardiovascular risk
whereas in the low FRS category subjects remain at low risk
for any level of CACS. Reproduced with permission from
reference 26
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while absence of relevant coronary calcification reclassifies individ-
uals to low risk (Figure 1).7
It has been suggested that an appropriate evaluation of the clini-
cal relevance of a new risk marker should be derived from the
actual number of subjects reclassified to more appropriate cat-
egories of risk from the application of the new marker, calculated
by the Net Reclassification Improvement (NRI) and by the Inte-
grated Discrimination Improvement (IDI) indices.27 Thus, these
indices are calculated to evaluate the additional number of subjects
in whom clinical events will occur, identified by the new risk
marker. Preliminary data from the Heinz Nixdorf Recall Study,28
a population-based study in 4327 randomly selected individuals
from the general population without known CAD, indicate that
CAC scoring of persons at intermediate risk results in an NRI of
21% (P ¼ 0.0003) after 5 years of follow-up, with an IDI of
1.52% (P, 0.0001). These data compare favourably with other
novel markers of risk.27,29,30
In summary, there is overwhelming evidence that coronary cal-
cification represents a strong marker of risk for future cardiovascu-
lar events in asymptomatic individuals and has prognostic power
above and beyond traditional risk factors. However, prospective
outcomes data from trials in which individuals are randomized to
receiving or not receiving a coronary calcium scan would be
required to firmly establish whether CAC imaging in intermediate
risk subjects ultimately results in reduced coronary events, pro-
vides improved clinical outcomes, and is cost-effective.
Coronary calcium in type 2 diabetic
patients
Patients with type 2 diabetes experience more diffuse, calcified,
and extensive CAD, more often have left ventricular dysfunction,
and more frequently have silent ischaemia. Consequently, diabetic
individuals have substantially higher cardiovascular event rates
than non-diabetic individuals without cardiovascular disease and,
even when asymptomatic, type 2 diabetics are considered at
high cardiovascular risk,31 so that secondary prevention strategies
are recommended.3,7 However, further risk stratification in
diabetic patients may help identify subjects with extensive
coronary atherosclerosis and with significant inducible silent
myocardial ischaemia,32,33 who would potentially benefit from
even more aggressive treatment strategies, including coronary
revascularization.
The presence of coronary calcium has proven predictive for
future cardiovascular events in asymptomatic diabetic individuals,
even though for any degree of CAC, mortality of diabetic individ-
uals is higher than in non-diabetic subjects.34 Assessment of CAC
may also aid in identifying diabetic individuals with a higher likeli-
hood of inducible ischaemia: in diabetic patients without prior car-
diovascular events, low CAC scores (‘Agatston Score’ ≤10) are
associated with a low prevalence of inducible myocardial ischaemia
and a low event rate.34,35 Use of CAC scoring for risk stratification
in asymptomatic diabetic patients is not currently endorsed by the
American Diabetes Association recommendations.36 However, if a
strategy of testing asymptomatic diabetic individuals for the pres-
ence of silent ischaemia is needed, pre-selection of individuals
based on calcium scores with the intent of performing subsequent
functional imaging in the presence of a substantial atherosclerotic
burden should therefore be considered.
Coronary calcium in the elderly and
in renal disease
Several studies have specifically addressed the prognostic value of
CAC in older subjects.37–39 These studies indicate that, like in
middle-aged subjects, low CAC scores are associated with a
favourable mid-term prognosis and event rates increase with
increasing amounts of coronary calcium. However, more data
are needed in older asymptomatic subjects to verify whether rec-
ommendations for different intensities of risk modification thera-
pies, based on the combination of age, risk factor burden, and
CAC scores, can be provided.
Impaired renal function is a major cardiovascular risk factor and
risk gradually increases as the glomerular filtration rate
decreases.40 Patients with impaired renal function have elevated
CAC scores and the prevalence and extent of CAC is especially
high in dialysis patients. Importantly, coronary calcification may
partly be due to non-atherosclerotic mechanisms in patients with
renal failure and on dialysis.41 Coronary artery calcium progresses
more rapidly in dialysis patients, in whom it correlates with age,
duration of dialysis, cause of chronic renal failure, diabetes mellitus,
alterations in mineral metabolism as well as use and dose of
calcium-based phosphate binders.42–44 The amount of CAC in
dialysis patients has been reported to be associated with cardiovas-
cular outcome.44 Similarly, non-coronary cardiac calcification
(e.g. calcification of the mitral annulus and non-coronary vascular
calcification) have also been shown to be associated with increased
mortality in patients with renal failure.45,46 However, dialysis
patients are candidates for intensive risk modification even
without the knowledge of calcium scores and additional data are
needed to assess the potential clinical use of CAC scoring for
further risk stratification of this population.
Measurement of coronary artery
calcium progression
The simplicity to obtain a CAC score makes it a potentially appeal-
ing tool for monitoring atherosclerosis burden over time, and the
implications of serial measurements have been recently
reviewed.42 At present, there is no consensus on the most appro-
priate definition of progression, i.e. whether using absolute score
differences, percent changes, or square root changes. Progression
of the calcium score averages 15–25% per year and is substantially
dependent on the baseline amount of calcium. It is also determined
by age, sex, family history of premature CAD, the ethnic back-
ground, diabetes, body mass index, elevated blood pressure, and
renal insufficiency.47–49 In some studies, rapid progression of
CAC, e.g. .15% per year, was associated with an increased risk
of events.47 Even though modification of CAC scores over time
has been reported under statin therapy in some trials,50,51
others52,53 have failed to reproduce these observations, including
the randomized SALTIRE trial in patients with aortic calcific steno-
sis treated with atorvastatin52 and it is unclear whether CAC pro-
gression is influenced by medications. Furthermore, the variability
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of repeated calcium scans is relatively high and a recent
meta-analysis from 10 prospective randomized trials in subjects
with CAD (5 trials) and in subjects with chronic renal disease (5
trials) suggests that the 1 year change in CAC burden may not
be a reliable endpoint for medical intervention trials53 and may
hence not be suitable to monitor the effect of preventive medi-
cations on clinical disease progression. Therefore, ‘serial’ or
‘repeated’ coronary calcium scans are currently not
recommendable.
Coronary computed tomography
angiography
After injection of contrast agent, coronary CT angiography allows
visualization of the coronary lumen and wall. Image quality of cor-
onary CT angiography depends on many factors and in selected
patients high accuracy for stenosis detection can be achieved. In
addition, coronary CT angiography allows the detection of both
calcified and also non-calcified plaque components, and, to a
certain extent, plaque quantification and characterization is poss-
ible. It has recently been shown that some characteristics of coron-
ary atherosclerotic plaques detected by coronary CT angiography,
such as positive remodelling and low CT attenuation of the athero-
sclerotic material, are associated with the occurrence of future
acute coronary syndromes.54 Several studies have been able to
demonstrate a prognostic value of atherosclerotic lesions detected
by coronary CT angiography.55–57 However, all these analyses
were retrospectively performed in individuals who had undergone
coronary CT angiography for clinical reasons, and it must therefore
be assumed that most of the included patients were symptomatic.
In asymptomatic individuals, the prognostic role of coronary CT
angiography is ill defined, as it was assessed in only one study
which included 1000 Korean subjects aged 35–75 years.58 In this
study, 22% of individuals had detectable coronary atherosclerosis
but only 5% showed significant stenosis. Coronary events occurred
exclusively in individuals with detectable plaques but most of them
were revascularizations triggered by the very fact that an athero-
sclerotic lesion had been detected, not necessarily demonstrating
a less favourable prognosis had coronary CT angiography not
been performed. Similarly, although a 26–36% prevalence of sig-
nificant CAD was reported in asymptomatic type 2 diabetic
patients,59,60 lack of follow-up makes the prognostic value of
these observations uncertain.
In addition, when considering current use of coronary CT angio-
graphy for risk stratification in asymptomatic individuals, it must be
taken into account the required injection of contrast agent and the
exposure of patients to substantially higher radiation doses com-
pared with coronary calcium measurements. However, due to
the availability of prospective and high-pitch helical scan tech-
niques, improved detector technology and reconstruction algor-
ithms coronary CT angiography can be optimized to reduce
radiation exposure to a dose similar to CAC examination. These
aspects will influence the ratio between risk and benefit, especially
in low-risk individuals.
To summarize, beyond the detection of coronary artery steno-
sis, coronary CT angiography has the potential for the detection
and characterization of coronary atherosclerosis. However, due
to the lack of favourable prognostic data in asymptomatic individ-
uals, it is currently not recommended for risk stratification in
primary prevention.61
Myocardial perfusion
scintigraphy
Myocardial perfusion scintigraphy in
asymptomatic subjects
The absence of inducible ischaemia at MPS identifies subjects with
very low (,1% per year) event rates during the following 2–3
years.62,63 The prevalence of silent myocardial ischaemia in asymp-
tomatic populations varies according to the characteristics of the
patient population screened.64,65 In non-diabetic patient popu-
lations, approximately 0.52–22% of subjects have evidence of
silent ischaemia, with an increase from 2% in the fifth and sixth
decades of life to 15% in the ninth decade.64
Only a few studies have specifically evaluated the value of MPS in
asymptomatic individuals with intermediate risk. Khandaker et al.65
recently showed, in 260 asymptomatic patients at moderate CAD
risk, that stress MPS was effective for detection and risk stratifica-
tion of CAD. Average annual mortality was 4.0% in patients with
high risk vs. 1.6% in patients with normal scans. Similar to what
were reported in a general patient population,14 it has been
shown in a general asymptomatic population that an extent of
ischaemia of more than 7.5% of left ventricular myocardium is
associated with a high risk of major cardiac events (cardiac death
or non-fatal MI).66 Of note, although in this last study, angina or
ischaemic ECG changes during stress testing were observed in
only 7 and 51%, respectively, these variables were predictors of
high-risk ischaemia at MPS, underscoring the fact that some
patients not reporting angina during daily life activities may
develop symptoms during adequate exercise testing.66 In addition,
known CAD risk factors (male gender, age, diabetes, and hyperten-
sion) and an abnormal resting ECG were independently predictive
of high-risk silent ischaemia suggesting that consideration of these
variables may facilitate identification of individuals that may benefit
from further evaluation by MPS.
Myocardial perfusion scintigraphy
in asymptomatic type 2 diabetic patients
A meta-analysis of 31 studies including 69 655 diabetic and non-
diabetic patients showed that the average annual hard event rate
(cardiac death or MI) in diabetic patients with a normal MPS was
0.85% as opposed to 5.9% in those with a moderately to severely
abnormal MPS.62 Yet, for any degree of perfusion abnormality, the
risk of diabetic patients is higher compared with non-diabetic
patient populations.67
Although stress imaging is recommended for symptomatic type 2
diabetics, there is still no consensus on the best approach for
screening asymptomatic diabetic subjects without known CAD35
in whom the prevalence of silent ischaemia, identified as perfusion
abnormalities, has been reported to be up to 59%.68,69 Recently,
Wackers et al.,70 in a contemporary population of 522
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asymptomatic diabetic patients with at least two risk factors
enrolled in the Detection of Silent Myocardial Ischemia in Asymp-
tomatic Diabetics (DIAD) study, reported a prevalence of 21%
abnormal MPS using gated 99mTc-sestamibi. Of note, conventional
risk factors did not predict perfusion abnormalities, whereas the
only independent predictor of an abnormal perfusion was the pres-
ence of autonomic cardiac neuropathy.
The prognostic value and clinical implications of ischaemia
detection in asymptomatic diabetic patients without known CAD
have been evaluated in a limited number of studies68,71,72 and
none of these studies tested whether screening asymptomatic dia-
betics with MPS would alter clinical outcome. This fundamental
aspect was investigated in the DIAD prospective trial73 which eval-
uated a population of about 1000 asymptomatic type 2 diabetics
randomized to a MPS vs. non-MPS assisted management and fol-
lowed up for 4.8 years. As expected, the presence of moderately
to large ischaemic defects was associated with a significantly higher
event rate (2.4% per year) compared with patients with normal
perfusion or small perfusion abnormalities (0.4% per year).
However, moderate to large perfusion defects occurred in only
33 (6%) of 561 patients.73 Thus, in summary, the trial showed no
difference in outcomes between the two strategies and a very
low (,1% per year) event rate in the whole population, due to
implementation of preventive therapies in both groups of patients,
thus potentially obscuring the benefit of ischaemia detection on
the primary endpoint.
These data can be interpreted in the context of the recent BARI
2D trial74 which compared medical therapy vs. revascularization in
type 2 diabetic patients with chronic CAD. Although the trial failed
to demonstrate a significant difference between the two treatment
strategies in the whole population, a significant benefit of revascu-
larization was observed in the pre-specified subgroup of patients
randomized to coronary artery bypass grafting in whom more
extensive CAD and more severe inducible ischaemia were
present. These two trials put together indicate that ischaemia
evaluation by MPS is not recommended as first line strategy in
unselected asymptomatic type 2 diabetics without known CAD
and with normal resting ECG.
In addition, the negative predictive ‘warranty period’ for a
normal MPS study has been reported to be shorter in diabetic
compared with non-diabetic patients but additional data would
be warranted to recommend an optimal and cost-effective time
interval between repeat evaluation in these subjects.75
Combination of coronary
calcium or coronary computed
tomography angiography with
myocardial perfusion scintigraphy
Comparative studies between either CAC or coronary CT angio-
graphy and functional imaging tests such as MPS have shown that
anatomical tests cannot accurately predict the haemodynamic rel-
evance of the detected atherosclerotic lesions.10 On the other
hand, functional tests may frequently underestimate the extent of
underlying atherosclerosis.13 Accordingly, these techniques yield
distinct information regarding the presence and severity of CAD
and their combination may potentially provide complementary
and incremental information for risk stratification. In patients
without known CAD, a correlation between CAC scores and func-
tionally significant CAD has been reported, with the negative pre-
dictive value of the calcium score for excluding coronary stenosis
ranging from moderate76 to high (.90%)77 and a positive predic-
tive value regarding inducible ischaemia of up to 50% for high
‘Agatston Scores’ (.400),77 depending on the characteristics of
the population studied.
The value of combining CAC scores and MPS (ischaemia) assess-
ment in non-diabetic subjects is not yet clear, since available data
are limited and yielded conflicting results. Schenker et al.76
reported that a high CAC score was associated with a stepwise
increase of major cardiac events (cardiac death and MI) in subjects
without known CAD and without typical angina, but with two or
more risk factors. This was observed both in the presence or
absence of inducible ischaemia, thus suggesting an incremental
role of the CAC score over perfusion abnormalities. In agreement
with this study, Chang et al.78 recently reported, in a population of
1126 asymptomatic subjects undergoing CAC imaging and MPS,
that in subjects with a normal MPS, coronary calcification added
incremental prognostic information, with a 3.55-fold relative
increase for any cardiac event (2.75-fold for death/MI) when calci-
fication was severe (‘Agatston Score’ .400) vs. minimal (‘Agatston
Score’ ,10). Interestingly, separation of the survival curves
occurred at 3 years after initial testing for all cardiac events and
at 5 years for death/MI, indicating an incremental mid- to long-term
prognostic value of the CAC score over MPS. In contrast, Rozanski
et al.,77 in an asymptomatic population at lower cardiovascular risk,
observed no increased risk in subjects without inducible ischaemia
but with high CAC scores.
In diabetic patients without history of CAD, Anand et al.,35
using a combined approach of CAC imaging and MPS, reported
abnormal MPS findings in 18% of patients with an ‘Agatston
Score’ between 10 and 100, in 48% of patients with an ‘Agatston
Score’ between 100 and 400 and in 71% of patients with ‘Agat-
ston Scores’ .1000, whereas no patients with absent or
minimal CAC (‘Agatston Score’ 0 to 10) showed abnormal MPS.
In addition, although only 20 cardiovascular events occurred in
this population during a follow-up interval of 2.2 years, no
event was observed in patients with absent or minimal coronary
calcification.
Thus, it needs to be recognized that while in intermediate risk
subjects, a two-step risk stratification strategy of an initial coronary
calcium scan, followed by selective MPS imaging in subjects with
high CAC scores sounds attractive and would be worth testing,
there is no definitive evidence to support any clinical benefit of
this approach. In contrast, based on Anand et al.’s35 study, it
seems conceivable that in asymptomatic type 2 diabetics without
known CAD, a CAC score followed by selective ischaemia evalu-
ation for subjects with significant ‘Agatston Scores’ (.10) should
be considered to identify candidates for invasive CAD assess-
ment.79 Thus, MPS would be potentially useful for those with evi-
dence of coronary atherosclerosis through a positive CAC scan or,
as first line test, in those with abnormal resting ECG, in agreement
with recommendations of the American Diabetes Association.36
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Asymptomatic diabetics with evidence of moderate to severe indu-
cible ischaemia at MPS should then undergo invasive coronary
angiography as they may benefit from revascularization.
Risk assessment in subjects with
familial hypercholesterolemia
(FH) and with familial history of
premature coronary artery disease
Subjects with familial hypercholesterolemia (FH) and relatives of
patients with premature CAD represent high-risk populations in
whom detection of premature CAD may be relevant for prognosis.
While non-invasive imaging by cardiac CT and MPS may play a role
in these individuals, currently available data are very limited.
In a group of 29 young subjects (,23 years old) with FH,
Gidding et al.80 reported a 24% prevalence of significant coronary
calcium. Similarly, Mouratidis et al.81 reported a 26% prevalence
of abnormal MPS in 54 adolescents and young adults with FH
(51 of them with heterozygote FH). However, no prognostic or
angiographic data were available in these studies, and, therefore,
the clinical and prognostic value of these findings remains
uncertain.
In subjects with familial history of premature CAD, the preva-
lence and extent of coronary calcium was investigated in 8549
asymptomatic individuals.82 Those without familial history, with
affected parents, or affected siblings had a coronary calcium preva-
lence of 55, 64, and 78% (P, 0.0001) among men and 27, 36, and
56% (P, 0.0001) among women, respectively. In a MPS study
which included 264 asymptomatic siblings of patients with prema-
ture CAD, abnormal 201Tl scans were observed in 29% of men and
9% of women, while abnormal exercise ECGs occurred in only 12
and 5%, respectively.83 Nineteen siblings developed clinical CAD
(sudden death in 1, MI in 10, coronary revascularization in 8)
over a mean of 6.2 years of follow-up. Although abnormal exercise
ECGs and 201Tl MPS were both predictive of future clinical CAD,
an abnormal MPS was associated with a 4.7 higher relative risk
after adjustment for age, sex, and exercise ECG results. Siblings
with a concordant abnormal exercise ECG and 201Tl scan had a
relative risk of 14.5.83
To test the relationship between CAC and inducible ischaemia
in these subjects, Blumenthal et al.84 studied 260 asymptomatic sib-
lings of patients with premature CAD. Abnormal MPS was
reported in 50% of subjects with ‘Agatston Scores’ .100, but
also in 21% of those with absent or minimal CAC (0 to 10 Agat-
ston score), indicating that the negative prognostic power of cor-
onary calcium for excluding significant CAD in this high-risk
population is suboptimal and, therefore, a strategy of screening
subjects for inducible-ischaemia based on previous coronary
calcium scans is not recommended.
To summarize, more prognostic studies are definitively needed
to assess the value of cardiac CT and MPS for stratification of sub-
jects who may have a baseline risk above the general population.
However, preliminary data indicate MPS may be considered in
asymptomatic subjects with FH or familial history of CAD.
Conclusions and perspectives from
the working group
The role of non-invasive cardiac imaging for risk stratification in
primary prevention has been considerably evolving in recent
years. Strong evidence indicates that coronary calcification pro-
vides effective, independent, and incremental risk stratification in
intermediate-risk subjects without known cardiovascular disease.
Table 2 Applications of CCT and myocardial perfusion scintigraphy in asymptomatic subjects without previous
cardiovascular events
P. Perrone-Filardi et al.1992
In addition, both coronary calcium and MPS provide prognostic
information in asymptomatic type 2 diabetic patients without
known CAD. Yet, there is currently no evidence that the use of
CAC imaging or MPS for risk stratification of asymptomatic sub-
jects without known cardiovascular diseases will favourably
impact on clinical outcome. Thus, both tests do not fully meet
appropriateness criteria for routine clinical use.85,86
In summary, the Working Group recognizes that there are cur-
rently no prospective outcome trials which would lend evidence to
primary prevention strategies which incorporate imaging studies
for the detection of coronary calcium, coronary atherosclerotic
plaque, or myocardial ischaemia in asymptomatic individuals.
However, given strong prognostic data collected in retrospective
trials and observational studies, several patient groups may poten-
tially benefit from imaging strategies for risk stratification in
primary prevention and the use of imaging may be reasonable,
after consideration of patient characteristics and the specific clini-
cal situation, in the following scenarios (with level of evidence C
for all) (Table 2):
† Coronary calcium evaluation should be considered in selected
intermediate-risk subjects. Detection of coronary calcium
would reclassify patients to high risk and qualify them for
according treatment (class of recommendation IIa).
† Myocardial perfusion imaging by MPS in unselected, asympto-
matic diabetic individuals is not recommended (class of rec-
ommendation III). However, the presence of coronary calcium
detected by cardiac CT preselects diabetic individuals with
increased likelihood for myocardial ischaemia in MPS. Asympto-
matic type 2 diabetic patients without known CAD should thus
be considered for coronary calcium imaging followed by MPS
for those with significant coronary calcium, in order to identify
subjects with a moderate to severe extent of ischaemia which
are likely to benefit from invasive evaluation and revasculariza-
tion (class of recommendation IIa).
† MPS may be considered a first-line test for first-degree
relatives of patients with premature CAD (class of recommen-
dation IIb).
Furthermore, the Working Group concludes:
† Coronary CT angiography is currently not recommended as a
screening tool in asymptomatic individuals (class of recommen-
dation III).
† Serial measurement of coronary calcium in order to ‘monitor’
progression of coronary atherosclerosis is not recommended
(class of recommendation III).
Finally, radiation exposure is of considerable concern in primary pre-
vention patients87,88 and under all circumstances imaging tests need to
be performed with the lowest possible radiation exposure. The
Working Group strongly supports further research (Table 3) regard-
ing the use of imaging for risk stratification, and specifically encourages
outcome trials to evaluate the clinical effects and cost-effectiveness of
imaging-based treatment algorithms in a randomized fashion.
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